A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer

• DOI: 10.1097/cad.0b013e328082558a
• Publication Date: 2007-08-02T07:01:26Z
• Authors: Carmelo G. Giorgio; Alessandro Pappal...; Antonio Russo; Daniele Santini; Carlo Di Rosa; Carmela Di Salvo; Sergio Castorina; Franco Marletta; Giuseppe Bellissima; Nuccio Palermo; Concetto Scuderi; Roberto Bordonaro
• Keywords: Carboplatin; Chemoradiotherapy; Concomitant; Induction chemotherapy

The optimal management of unresectable locally advanced non-small-cell lung cancer in older patients has not been defined to date. present phase II study was planned evaluate the activity and safety platinum-based induction chemotherapy followed by concurrent chemoradiotherapy elderly with cancer. Patients received two cycles paclitaxel (175 mg/m2) carboplatin (area under curve: 5) day 1, every 3 weeks. Chemoradiotherapy (thoracic radiation therapy) initiated on 42 consisted 1.8 Gy daily, five times per week over 5 weeks (45.0 target dose) 10 2.0 daily fractions. Concomitant weekly 50 mg/mq at an area curve 2. eligibility for patients: age 70 or histologically documented untreated cancer, advanced, unresectable, stage III A N2 bulky B. Thirty consecutive were enrolled onto study. median 73 (range 70–76). According intention-to-treat analysis, 1 month after end combined chemoradiotherapy, we observed complete partial responses one 19 30 patients, respectively, overall response rate 66% (95% confidence interval, 45–76%). Median progression-free survival 8.7 months 3.4–37.8) 15 4.2–52.1). During treatment, 12 (40.0%) experienced grade 3–4 neutropenia, neutropenic fever, three anaemia thrombocytopenia, respectively. Grade oesophagitis, during concomitant radiotherapy, six (20.0%). No treatment-related mortality reported. investigated sequential approach including appears safe seems a reasonable chance treatment population.